Thursday, July 10, 2025
  • Login
Euro Times
No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
Euro Times
No Result
View All Result

Eisai, Biogen Alzheimer’s drug slows cognitive decline, safety for some becomes focus By Reuters

by Reuters
November 30, 2022
in Stock Market
Reading Time: 3 mins read
A A
0
Home Stock Market
Share on FacebookShare on Twitter


2/2

© Reuters. FILE PHOTO: The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato/File Photo

2/2

By Deena Beasley

SAN FRANCISCO (Reuters) – An experimental Alzheimer’s disease drug from Eisai and Biogen (NASDAQ:) slowed cognitive decline in a closely-watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday.

The drug, lecanemab, was associated with a type of brain swelling in 12.6% of trial patients, a side effect previously seen with similar drugs. Fourteen percent of patients had microhemorrhages in the brain – a symptom linked to two recent deaths of people receiving lecanemab in a follow-on study – and five patients suffered macrohemorrhages.

The companies said in September that the 18-month trial, which enrolled nearly 1,800 participants with early-stage Alzheimer’s, found that treatment with lecanemab reduced the rate of decline on a clinical dementia scale (CDR-SB) by 27% compared to a placebo.

“All of these amyloid-lowering drugs carry a risk for increased brain hemorrhage,” said Dr. Ronald Petersen of the Mayo Clinic in Rochester, Minnesota. “I think the primary outcomes, the secondary outcomes, the amyloid-lowering is pretty impressive.”

The trial showed no benefit on the CDR-SB measure for some patients with a genetic risk of developing the mind-wasting disease.

About 16% of trial participants had two copies (homozygous) of the APOE4 gene variant known to raise the risk of developing Alzheimer’s, 53% had one copy of the gene (heterozygous), and 31% were noncarriers.

“For that small group of homozygous patients, when it comes to CDR-SB we don’t see a signal favoring lecanemab,” Ivan Cheung, Eisai’s U.S. chairman, said in an interview. He suggested that could be because homozygous study patients who were given a placebo fared better than expected.

The APOE4 carriers did show improvement on the trial’s secondary goals, including other measures of cognition and daily function. Overall, lecanemab patients benefited by 23% to 26% compared with a placebo on these secondary trial goals.

“I believe it’s an important benefit that will justify full approval. But of course, we want a bigger benefit,” said Dr. Paul Aisen, director of the University of Southern California Alzheimer’s Therapeutic Research Institute and a co-author of the study. He said lecanemab is likely to provide greater benefit if given earlier in the disease, “before you’ve accumulated enough irreversible damage to be causing symptoms.”

Detailed data from the study were presented at the Clinical Trials on Alzheimer’s Disease meeting in San Francisco and published in the New England Journal of Medicine.

PROOF OF AMYLOID THEORY

Eisai believes the trial results prove a longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer’s can delay advance of the debilitating disease.

At 18 months, 68% of trial participants treated with lecanemab had amyloid clearance, Eisai said.

On Sunday, the journal Science reported the death of a 65-year-old woman who was being treated with lecanemab. After suffering a stroke, the woman received a type of medicine known as tissue plasminogen activator to clear blood clots and suffered a brain hemorrhage.

Earlier this year, Stat reported that an 87-year-old man in the study, who was on the blood thinner Eliquis, also developed a brain hemorrhage and died.

Eisai said it believes that the two deaths “cannot be attributed to lecanemab.”

Cheung said Eisai has protocols in place for monitoring brain swelling and sees no need for restrictions on which patients might be eligible for lecanemab treatment.

Dr. Howard Fillit, chief science officer at the Alzheimer’s Drug Discovery (NASDAQ:) Foundation, said doctors always balance the benefits and risks of therapies. “Currently, I would hesitate to give this drug to someone on blood thinners,” he said.

The U.S. Food and Drug Administration is slated to decide by Jan. 6 whether to approve lecanemab under its “accelerated” review program, which requires proof that a drug can impact a biomarker associated with a disease, such as reduction of amyloid beta in the brain.

Regardless of that decision, Cheung said Eisai plans to soon thereafter file for standard FDA approval of the drug, based on its recent efficacy and safety data. The company also plans to seek approval in Europe and Japan.



Source link

Tags: AlzheimersBiogenCognitivedeclinedrugEisaiFocusReutersSafetySlows
Previous Post

10 Top Electric Utility Stocks For Reliable Dividends

Next Post

Japan’s Oct factory output falls again on global slowdown, weak chip demand By Reuters

Related Posts

Nu Holdings: The Fintech Stock With Strong Long-Term Growth Potential (NYSE:NU)

Nu Holdings: The Fintech Stock With Strong Long-Term Growth Potential (NYSE:NU)

by Analysis Fundamental
July 9, 2025
0

This text was written byComply withI'm an skilled Threat Administration Enterprise Analyst at a Systemic Greek Financial institution, with a...

Antofagasta: Robust Prospects For Long-Term Dividend Investors (ANFGF)

Antofagasta: Robust Prospects For Long-Term Dividend Investors (ANFGF)

by Alberto Abaterusso
July 9, 2025
0

This text was written byObserveAlberto holds a Grasp's diploma in Enterprise Economics. Throughout his educational profession he acquired an in...

Oklo: The Most Exciting Zero-Revenue Stock (NYSE:OKLO)

Oklo: The Most Exciting Zero-Revenue Stock (NYSE:OKLO)

by Michael Wiggins De Oliveira
July 8, 2025
0

This text was written byObserveMichael Wiggins De Oliveira is an inflection investor. This implies shopping for into low cost corporations...

B-Stock’s Summer Teammate Spotlight 2025: Meet Mia Paulding

B-Stock’s Summer Teammate Spotlight 2025: Meet Mia Paulding

by Andrea Vargas
July 8, 2025
0

B-Inventory is so excited to welcome Mia Paulding to the Purchaser Account Administration staff this summer time! As a summer...

B-Stock’s Summer Teammate Spotlight 2025: Meet Alyssa Shum

B-Stock’s Summer Teammate Spotlight 2025: Meet Alyssa Shum

by Andrea Vargas
July 8, 2025
0

B-Inventory is so excited to welcome Alyssa Shum to the Product Design group this summer time! As a summer time...

Dell Stock Is Fairly Valued With CSG Struggles (NYSE:DELL)

Dell Stock Is Fairly Valued With CSG Struggles (NYSE:DELL)

by Jia Ming Eow
July 7, 2025
0

This text was written byObserve19 12 months previous passionate dealer managing a 6 determine portfolio attempting to and beating the...

Next Post
Japan’s Oct factory output falls again on global slowdown, weak chip demand By Reuters

Japan's Oct factory output falls again on global slowdown, weak chip demand By Reuters

Sam Bankman-Fried reveals the circumstances behind Bahamian withdrawals

Sam Bankman-Fried reveals the circumstances behind Bahamian withdrawals

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

“Calling All Crypto Transactions Externalization Would Be Very Limiting,” Warns FMAS:25 Panel

“Calling All Crypto Transactions Externalization Would Be Very Limiting,” Warns FMAS:25 Panel

July 10, 2025
Why Is Every Natural Disaster Being Politicized?

Why Is Every Natural Disaster Being Politicized?

July 10, 2025
Court in Moldova Extends House Arrest of Gagauzia Head Gutsul for 30 Days

Court in Moldova Extends House Arrest of Gagauzia Head Gutsul for 30 Days

July 10, 2025
Pentagon to become largest shareholder in rare earth magnet maker MP Materials

Pentagon to become largest shareholder in rare earth magnet maker MP Materials

July 10, 2025
Saratoga Investment Q1: ROE Beating The BDC Industry Average (NYSE:SAR)

Saratoga Investment Q1: ROE Beating The BDC Industry Average (NYSE:SAR)

July 10, 2025
The Emptiness of AI Ethics

The Emptiness of AI Ethics

July 10, 2025
Euro Times

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Finance
  • Health
  • Investing
  • Markets
  • Politics
  • Stock Market
  • Technology
  • Uncategorized
  • World

LATEST UPDATES

“Calling All Crypto Transactions Externalization Would Be Very Limiting,” Warns FMAS:25 Panel

Why Is Every Natural Disaster Being Politicized?

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In